Compare STBA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | NBTX |
|---|---|---|
| Founded | 1902 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1995 | 2018 |
| Metric | STBA | NBTX |
|---|---|---|
| Price | $46.32 | $35.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $43.00 | $36.00 |
| AVG Volume (30 Days) | ★ 197.2K | 53.7K |
| Earning Date | 04-23-2026 | 03-31-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 2.35 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.20 | $58.17 |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $50.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.01 | $4.46 |
| 52 Week High | $48.70 | $57.14 |
| Indicator | STBA | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 44.87 |
| Support Level | $42.52 | $30.15 |
| Resistance Level | N/A | $41.89 |
| Average True Range (ATR) | 1.10 | 2.49 |
| MACD | 0.10 | -0.29 |
| Stochastic Oscillator | 48.55 | 45.58 |
S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.